<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784080</url>
  </required_header>
  <id_info>
    <org_study_id>H-15007823</org_study_id>
    <nct_id>NCT02784080</nct_id>
  </id_info>
  <brief_title>Donor Specific HLA Alloantibodies in Liver Transplantation</brief_title>
  <official_title>Donor Specific HLA Alloantibodies in Liver Transplantation: a Prospective Blinded Multicenter Prognostic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to evaluate the impact of donor specific HLA alloantibodies (DSA) on all-cause
      mortality and re-transplantation, early allograft dysfunction, acute and chronic rejection,
      fibrosis, vascular, and biliary complications. Furthermore, all biopsies will be C4d stained.
      The hypothesizes is that donor specific HLA alloantibodies facilitate an immune mediated
      damage to the liver allograft that impairs function and lead to various complications.

      The investigators will do a prospective blinded multicenter cohort study in the
      Scandiatransplant organ sharing organization region.

      Both preformed, persistent, and de novo donor specific HLA alloantibodies will studied. Blood
      samples will be taken immediately prior to transplantation, and 14 days, 3 months, and 1 year
      after transplantation. All liver biopsies performed during the study period will be evaluated
      for a humoral component and blood samples will be obtained prior to liver biopsies to
      investigate the presence of DSA.

      Investigations will be fully blinded for the treatment responsible doctors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The outcome after liver transplantation has improved drastically over time, but this
      development has stagnated in recent years to a graft failure rate of 9-15 % within the first
      year and approximately 20-30 % at 5 years [1]. The primary goal is to improve the outcome
      after liver transplantation.

      The impact of donor specific antibodies (DSA) on all-cause mortality and re-transplantation,
      early allograft dysfunction, acute and chronic rejection, vascular and biliary complications
      and fibrosis will be investigated.

      Objectives:

        1. The primary objective is to investigate if DSA both pre-formed, persistent, and de novo
           affect survival and allograft loss. For patients diagnosed with HLA antibodies a
           standard Luminex single antigen IgG analysis, a Luminex C1q and an IgG3 single antigen
           assay will be performed.

        2. The secondary objective is to investigate if donor specific antibodies, both pre-formed,
           persistent, and de novo increase the risk of early allograft dysfunction, acute and
           chronic rejection, fibrosis, de novo autoimmune hepatitis (pediatric patients only),
           vascular and biliary complications. All liver biopsies will be stained by C4d and a DSA
           analysis will be undertaken.

        3. Continuous measurements will be used to establish the kinetics of both preformed og de
           novo DSA after liver transplantation.

      Pediatric patients will be analyzed separately.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality or re-transplantation (graft loss)</measure>
    <time_frame>Minimum 1 year, accrual to study end</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early allograft dysfunction are defined as total bilirubin &gt;10 mg/dl or INR &gt;1.6 at day 7 after liver transplantation or ALT &gt;2000 IU/L within the first 7 days after liver transplantation.</measure>
    <time_frame>7 days after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute rejection, both cellular and humoral rejection, as defined by Banff classification.</measure>
    <time_frame>Minimum 1 year, accrual to study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic rejection, as defined by Banff classification, and as proposed by O'leary et al &quot;Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts&quot;.</measure>
    <time_frame>Minimum 1 year, accrual to study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis, defined by METAVIR score.</measure>
    <time_frame>Minimum 1 year, accrual to study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular complications (hepatic arterial stenosis, hepatic arterial thrombosis, portal vein thrombosis).</measure>
    <time_frame>Minimum 1 year, accrual to study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biliary complications (biliary leakage, anastomotic biliary stricture, non-anastomotic biliary stricture, liver abscess, cholangitis, other).</measure>
    <time_frame>Minimum 1 year, accrual to study end</time_frame>
    <description>Anastomotic strictures and non-anastomotic strictures will be investigated as a combined and solitary outcome.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1162</enrollment>
  <condition>Complication of Transplanted Liver</condition>
  <arm_group>
    <arm_group_label>HLA-alloantibodies exposure</arm_group_label>
    <description>Preformed, persistent, and de novo HLA-alloantibody exposure in the whole cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HLA-alloantibodies exposure</intervention_name>
    <description>Following analyzes will be done:
LABScreen® Mixed, One Lambda, CA LABScreen® Single Antigen, One Lambda, CA C1qScren™, One Lambda, CA PE-conjugated IgG3 antibody</description>
    <arm_group_label>HLA-alloantibodies exposure</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Recipient samples, pre-transplant, at discharge or day 14 (±4 days), 3 months (±3 weeks), 1
      year (±1 month, and at liver biopsy

        -  1 Plasma, EDTA-glass (9 ml), redistributed 4 aliquots

        -  2 Serum, clot activator (9 ml + 4 ml), redistributed 8 aliquots

        -  Liver biopsy sample: Formalin fixed paraffin-embeded
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All liver transplant recipients, both children and adults, in the Scandiatransplant region.
        The Scandiatransplant is an organ exchange organization that comprise of five centers in
        the Nordic countries: Norway, Sweden, Finland and Denmark. The five centers cover the need
        for liver transplantation in approximately 25 million people. From 2010-2015 the following
        number of transplants were done in Scandiatransplant according to the number of available
        donors: 323, 352, 353, 365, 388, and 401.

        Preliminary sample size calculations have estimated inclusion of 1062 adult and 100
        pediatric patients during a study period of 3 years. Interim sample size calculations will
        be done, if necessary the study period will be prolonged.

        Pediatric patients will be analyzed separately.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergo a liver transplanted during the study period.

          -  Pre-transplant serum sample of minimum 4 ml (relevant for pediatric patients)

          -  Informed consent is given.

        Exclusion Criteria:

          -  Withdrawal of informed consent.

          -  Blinding broken in a non-protocoled manner the patient will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan Rasmussen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Surgical Gastroenterology and Transplantation, Rigshospitalet - Copenhagen University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas A Rostved, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgical Gastroenterology and Transplantation, Rigshospitalet - Copenhagen University Hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helle Bruunsgaard, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Department of Clinical Immunology, Centre of Diagnostic Investigation, Rigshospitalet - Copenhagen University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas A Rostved, MD</last_name>
    <phone>+4521787364</phone>
    <email>andreas.arendtsen.rostved@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carina L Sørensen, BSN</last_name>
    <phone>+4535457495</phone>
    <email>carina.lund.soerensen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Surgical Gastroenterology and Transplantation, Rigshospitalet - Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carina L Sørensen, BSN</last_name>
      <phone>+4535457495</phone>
      <email>andreas.arendtsen.rostved@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Andreas A Rostved, MD</last_name>
      <phone>+4521787364</phone>
      <email>carina.lund.soerensen@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas A Rostved, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allan Rasmussen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helle Bruunsgaard, MD, DMSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Transplantation and Liver Surgery Clinic, Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>PL 372, 00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helena Isoniemi, MD, PhD</last_name>
      <email>Helena.Isoniemi@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Helena Isoniemi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johanna Arola, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Transplantation Medicine, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pål-Dag Line, MD, PhD</last_name>
      <email>pline@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Pål-Dag Line, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Surgery Department, Transplantation and Liver Surgery Unit, Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Bennet, MD, PhD</last_name>
      <email>william.bennet@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>William Bennet, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Castedal, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Transplantation Surgery, Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carl Jons, MD, PhD</last_name>
      <phone>+46762721845</phone>
      <email>carl.jorns@ki.se</email>
    </contact>
    <investigator>
      <last_name>Bo-Göran Ericzon, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carl Jons, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Kim WR, Smith JM, Skeans MA, Schladt DP, Schnitzler MA, Edwards EB, Harper AM, Wainright JL, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2012 Annual Data Report: liver. Am J Transplant. 2014 Jan;14 Suppl 1:69-96. doi: 10.1111/ajt.12581.</citation>
    <PMID>24373168</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Andreas Arendtsen Rostved</investigator_full_name>
    <investigator_title>MD, Ph. D. student</investigator_title>
  </responsible_party>
  <keyword>Liver Transplantation</keyword>
  <keyword>HLA alloantibodies</keyword>
  <keyword>donor specific antibodies</keyword>
  <keyword>Mortality</keyword>
  <keyword>Re-transplantation</keyword>
  <keyword>Rejection</keyword>
  <keyword>Acute rejection</keyword>
  <keyword>Chronic rejection</keyword>
  <keyword>Biliary complications</keyword>
  <keyword>Biliary stricture</keyword>
  <keyword>Arterial thrombosis</keyword>
  <keyword>Arterial stenosis</keyword>
  <keyword>Portal vein thrombosis</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>Single antigen bead</keyword>
  <keyword>Cross-match</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoantibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

